NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Revenue and Earnings forecasts and estimates accuracy
Dividend yield, history and sustainability
Financial position and solvency of the company